Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

Summary

Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class A patients, but the result for Child-Pugh class B patients is unclear.

Timeline

Start

2013-08-01

Primary completion

2016-01-30

Completion

2016-07-30

Drugs

Indications